NCT03468725View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2018

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions

Healthy Male Volunteers

Interventions

DRUG

XPF-008

Capsule filled with XEN1101

DRUG

Microcrystalline Cellulose

Placebo capsule

Trial Locations (1)

SE5 9RS

King's College Hospital, Brixton

All Listed Sponsors

lead

Xenon Pharmaceuticals Inc.

INDUSTRY

NCT03468725 - Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 | Biotech Hunter | Biotech Hunter